Capping the price of GLP-1s

  1. Research briefs
  2. Economics & Labor
  3. Capping the price of GLP-1s

Capping the Price of GLP-1s: Quantitative Analysis and Recommendations for Weight Loss Drug Policies in the United States

Team
Economics & Labor team, Harvard IOP Policy Program
Published
Fall 2025
Format
Full report, PDF, open access
Read the full brief (PDF)

Summary

Examines how high demand and limited competition have made GLP-1 drugs such as Ozempic and Wegovy prohibitively expensive, compares coverage abroad, and recommends a federal price cap modeled on the insulin cap alongside reforms to pharmacy benefit managers and FDA approvals.

Recommendations

  1. Implement mandatory federal price caps on GLP-1s based on international pricing standards
  2. Mandate Medicaid coverage for weight management in states with large food-desert populations
  3. Require fixed fees instead of rebates or spread pricing for pharmacy benefit managers, and enforce PBM transparency
  4. Streamline FDA approval of compounded and generic GLP-1 medications
  5. Extend FDA direct-to-consumer advertising rules to social media and influencer promotion

Keywords

  • GLP-1
  • Drug Pricing
  • Price Caps
  • Pharmacy Benefit Managers
  • Obesity
  • Health Disparities

Suggested citation

Economics & Labor Research Team. (2025). Capping the Price of GLP-1s: Quantitative Analysis and Recommendations for Weight Loss Drug Policies in the United States. Harvard Institute of Politics Policy Program. https://harvard-policy.github.io/policy/briefs/capping-glp1-prices.html

Full brief

Open access PDF.

Download PDF

Authors

  • Team leads: Tino Karakousis and Neil Tivakaran
  • Researchers: Safa Ahmad, Ruby Arun, Ashton Fulton, Austin Li, Rina Matsunaga, Runa Matsushita, James Miller, Kaia Patterson, Jack Rubin, Akilan Sankaran, Ellis Schroeder, Colin Williams
  • Program chairs: Natalie Jones and Christopher Shin

Identifier

Stable landing page:

harvard-policy.github.io/policy/briefs/capping-glp1-prices.html